ConspectusMolecular imaging holds considerable promise for elucidating biological
processes in normal physiology as well as disease states, by determining
the location and relative concentration of specific molecules of interest.
Proton-based magnetic resonance imaging (1H MRI) is nonionizing
and provides good spatial resolution for clinical imaging but lacks
sensitivity for imaging low-abundance (i.e., submicromolar) molecular
markers of disease or environments with low proton densities. To address
these limitations, hyperpolarized (hp) 129Xe NMR spectroscopy
and MRI have emerged as attractive complementary methodologies. Hyperpolarized
xenon is nontoxic and can be readily delivered to patients via inhalation
or injection, and improved xenon hyperpolarization technology makes
it feasible to image the lungs and brain for clinical applications.In order to target hp 129Xe to biomolecular targets
of interest, the concept of “xenon biosensing” was first
proposed by a Berkeley team in 2001. The development of xenon biosensors
has since focused on modifying organic host molecules (e.g., cryptophanes)
via diverse conjugation chemistries and has brought about numerous
sensing applications including the detection of peptides, proteins,
oligonucleotides, metal ions, chemical modifications, and enzyme activity.
Moreover, the large (∼300 ppm) chemical shift window for hp 129Xe bound to host molecules in water makes possible the simultaneous
identification of multiple species in solution, that is, multiplexing.
Beyond hyperpolarization, a 106-fold signal enhancement
can be achieved through a technique known as hyperpolarized 129Xe chemical exchange saturation transfer (hyper-CEST), which shows
great potential to meet the sensitivity requirement in many applications.This Account highlights an expanded palette of hyper-CEST biosensors,
which now includes cryptophane and cucurbit[6]uril (CB[6]) small-molecule
hosts, as well as genetically encoded gas vesicles and single proteins.
In 2015, we reported picomolar detection of commercially available
CB[6] via hyper-CEST. Inspired by the versatile host–guest
chemistry of CB[6], our lab and others developed “turn-on”
strategies for CB[6]-hyper-CEST biosensing, demonstrating detection
of protein analytes in complex media and specific chemical events.
CB[6] is starting to be employed for in vivo imaging
applications. We also recently determined that TEM-1 β-lactamase
can function as a single-protein reporter for hyper-CEST and observed
useful saturation contrast for β-lactamase expressed in bacterial
and mammalian cells. These newly developed small-molecule and genetically
encoded xenon biosensors offer significant potential to extend the
scope of hp 129Xe toward molecular MRI.